# Tirzepatide Side Effects Observed in Clinical Research — GI Events, Safety Profile, and Contraindications

> Tirzepatide side effects from the SURPASS and SURMOUNT trials: nausea, diarrhea, thyroid C-cell findings in rodents, gallbladder risk, and contraindications from the trial literature.

## What Are the Side Effects of Tirzepatide?

The most common adverse events in tirzepatide trials are gastrointestinal. Pooled analysis of SURPASS-1 through SURPASS-5 (n=6,263) documented [13]:

- **Nausea:** 12–24% with tirzepatide vs. 3–10% with comparators
- **Diarrhea:** 12–22%
- **Vomiting:** 2–13%
- **Constipation:** 5–12%

These events were predominantly mild-to-moderate, most frequent during dose escalation, and typically resolved within 4–8 weeks of stable dosing [13]. GI adverse events contributed less than 6% of tirzepatide's superior weight loss vs. comparators in mediation analysis [13].

## Serious Adverse Events Reported in Tirzepatide Trials

**Pancreatitis:** Meta-analysis of 9 RCTs (n=9,871) found no statistically significant association (RR 1.46, 95% CI 0.59–3.61) [15].

**Gallbladder/biliary disease:** Elevated composite risk vs. placebo or basal insulin (RR 1.97, 95% CI 1.14–3.42) [15]. Proposed mechanism: GLP-1R-mediated suppression of cholecystokinin impairing gallbladder motility.

**Hypoglycemia:** Rare with monotherapy; elevated when combined with insulin or sulfonylureas [4, 14].

**SURPASS-CVOT:** Noninferiority to dulaglutide for MACE over 4 years; all-cause mortality 16% lower with tirzepatide [19]. No new safety signals.

## Tirzepatide and Thyroid C-Cell Findings in Animal Research

Rodent carcinogenicity studies showed dose-dependent thyroid C-cell hyperplasia and adenomas/carcinomas at supratherapeutic exposures [14]. Human thyroid C-cells express negligible GLP-1R; no excess thyroid cancer risk has been detected in human clinical trials. An FDA boxed warning is required as a class effect [14].

## Tirzepatide GI Tolerability vs. Other GLP-1 Agonists

SURMOUNT-5 head-to-head (15 mg vs. semaglutide 2.4 mg): nausea incidence slightly higher with tirzepatide, but overall GI discontinuation rates broadly comparable [23]. Tirzepatide's greater efficacy is not traded off against substantially worse GI tolerability [8, 23].

## Contraindications Identified in Tirzepatide Research

Trial exclusion criteria and regulatory review established [14]:

- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2 (MEN2)
- Severe gastrointestinal disease (gastroparesis, inflammatory bowel disease)
- Pregnancy

## Drug Interactions and Precautions

1. Oral medications with narrow absorption windows — transient gastric emptying delay (primarily first weeks) can reduce absorption [14, 25].
2. Sulfonylureas and insulin — concurrent use increases hypoglycemia risk [4].
3. High-fat meals during titration — increases GI adverse events [13, 14].

## Long-Term Safety Profile

SURPASS-CVOT provides up to 4 years of safety data (n=13,299); no new safety signals emerged [8, 19]. SURMOUNT-1 three-year extension showed sustained weight loss with no late-emerging safety signals [20].

## References

[3] Frías JP, et al. SURPASS-2. N Engl J Med. 2021;385(6):503-515.
[4] Del Prato S, et al. SURPASS-4. Lancet. 2021;398(10313):1811-1824.
[5] Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387(3):205-216.
[7] Aronne LJ, et al. SURMOUNT-4. JAMA. 2024;331(1):38-48.
[8] Jastreboff AM, et al. SURMOUNT-5. N Engl J Med. 2025;393(1):26-36.
[10] Urva S, et al. Diabetes Obes Metab. 2020;22:1886-1891.
[13] Patel H, et al. GI AEs in SURPASS. Diabetes Obes Metab. 2024;26(2):473-481.
[14] U.S. FDA. Tirzepatide Prescribing Information. 2024.
[15] Zeng Q, et al. Front Endocrinol. 2023;14:1214334.
[19] Nicholls SJ, et al. SURPASS-CVOT. N Engl J Med. 2025;393:2409-2420.
[20] Jastreboff AM, et al. SURMOUNT-1 3yr. N Engl J Med. 2025;392(13):1227-1239.
[23] Jastreboff AM, et al. SURMOUNT-5 GI tolerability. N Engl J Med. 2025;393(1):26-36.
[25] U.S. FDA. Tirzepatide Drug Interactions. 2024.

---

The tirzepatide clinical record — mechanism, trials, and pharmacokinetics — read from primary sources, cited numerically, and held by no clinic and no vendor.